Trial reportContemporary clinical trials2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.
Trial report in Contemporary clinical trials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01077310 (Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Interventions for female drug-using offenders.The Cochrane database of systematic reviews · 2019Pooled it
- Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.Substance abuse · 2021Trial
- Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.Drug and alcohol dependence · 2017Trial
- Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Drug and alcohol dependence · 2015Trial
- Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Contemporary clinical trials · 2014Trial
- An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.Journal of substance abuse treatment · 2014Trial
- Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.Patient preference and adherence · 2021Review
- Interventions for drug-using offenders with co-occurring mental health problems.The Cochrane database of systematic reviews · 2019Review
- Reduced Sexual Risk Behaviors Among Persons With HIV After Release From the Criminal Justice System.Open forum infectious diseases · 2019Article
- Prisons: ignore them at our peril.Current opinion in HIV and AIDS · 2019Review
- A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.Journal of substance abuse treatment · 2018Article
- Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.Drug and alcohol dependence · 2017Article
- A Qualitative Assessment of Alcohol Consumption and Sexual Risk Behaviors Among Men Who Have Sex With Men and Transgender Women in Peru.Substance use & misuse · 2017Article
- The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis.AIDS and behavior · 2017Article
- Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence.Translational psychiatry · 2015Article
- Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru.AIDS care · 2015Article
- Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic.Journal of community health · 2014Article
- Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention.Current HIV/AIDS reports · 2014Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundHIV-infected prisoners have a high prevalence of alcohol use disorders and commonly relapse to alcohol soon after release to the community which is linked to high morbidity, poor antiretroviral therapy (ART) adherence and increased sexual risk-taking behaviors. Extended-release naltrexone (XR-NTX) effectively reduces relapse to alcohol in alcohol dependent persons, yet it remains unexamined among criminal justice system (CJS) populations transitioning to the community.
methodsA randomized double-blind, placebo-controlled trial of XR-NTX to improve HIV treatment outcomes via reducing relapse to alcohol use after prison release for HIV-infected hazardous drinking and alcohol dependent prisoners is discussed.
resultsAcceptability of study participation is high with 86% of those referred who met eligibility criteria and 85% of those who were able to receive injections prior to release accepted injections, yet important implementation issues are identified and addressed during the study and are discussed in this paper.
conclusionMedication-assisted therapies for prevention of relapse to alcohol use for CJS populations transitioning to the community, especially for HIV-infected patients, are urgently needed in order to reduce alcohol relapse after release and improve HIV treatment outcomes and contribute to improved individual and public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.